FIELD: biotechnology.
SUBSTANCE: present invention relates to methods for selective reduction of CysL97 in a preparation of secukinumab antibodies which are recombinantly produced by mammalian cells. Also provided is a purified preparation of secukinumab antibodies obtained by said methods, wherein the level of intact secukinumab antibodies is at least approximately 90 % and wherein the activity level of the secukinumab antibodies in said preparation is at least about 90 %.
EFFECT: selective reduction of cysteine residues in anti-il-17 antibodies is proposed.
17 cl, 14 ex, 17 dwg, 52 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN ANTIBODIES AGAINST IL-17 | 2015 |
|
RU2765307C2 |
| LIQUID COMPOSITION CONTAINING ANTIBODY TO HUMAN INTERLEUKIN-4 RECEPTOR ALPHA | 2020 |
|
RU2814172C2 |
| VERSIONS OF PERTUZUMAB AND THEIR ANALYTICAL CHARACTERISTICS | 2014 |
|
RU2737727C2 |
| VERSIONS AND ISOFORMS OF ANTIBODIES WITH REDUCED BIOLOGICAL ACTIVITY | 2018 |
|
RU2813990C2 |
| STRUCTURE OF POLYPEPTIC ANTIBODIES | 2015 |
|
RU2725812C2 |
| POLY-SPECIFIC ANTIBODY STRUCTURES | 2015 |
|
RU2784673C2 |
| MULTISPECIFIC ANTIBODY WITH BINDING SPECIFICITY OF HUMAN IL-13 AND IL-17 | 2020 |
|
RU2827946C1 |
| PHARMACEUTICAL COMPOSITION BASED ON IL-15 PROTEIN COMPLEX AND APPLICATIONS THEREOF | 2018 |
|
RU2749342C1 |
| MONOCLONAL ANTIBODIES TO INTERLEUKIN-31 FOR VETERINARY USE | 2019 |
|
RU2795411C2 |
| METHOD FOR OBTAINING BI-SPECIFIC ANTIBODIES, BI-SPECIFIC ANTIBODIES AND THERAPEUTIC APPLICATION OF SUCH ANTIBODIES | 2018 |
|
RU2795240C2 |
